Depression costs U.S. employers $83 billion annually, with treatment-resistant depression accounting for over half of that cost. On average, these patients cost $8,500 more per year than patients with ordinary depression. rEEG is the first objective, physiology-based, personalized medical technology consistently shown to guide psychiatrists to appropriate treatment for the most challenging patients.

The CNS Response study, the largest in the company's history, was a randomized, blinded, controlled, parallel group, multicenter study. The patients in the study experienced depression treatment failure of one of more SSRIs and/or had failure with at least two classes of antidepressants. The patients fell into two groups: 1) those treated with rEEG medication guidance, and 2) those treated with the modified STAR*D treatment algorithm.

"This is the promise of personalized medicine, tailoring therapies to the unique medication response profile of each individual patient," said George Carpenter, chief executive officer of CNS Response, Inc., which developed the patented technology. "Those suffering from the most resistant forms of depression will now have an effective treatment option, and doctors will no longer have to play an extended and costly guessing game to see what works best."

SOURCE: CNS Response, Inc.